Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020:159:34-53.
doi: 10.1016/j.addr.2020.05.008. Epub 2020 May 30.

Insights into incretin-based therapies for treatment of diabetic dyslipidemia

Kerstin Stemmer  1 , Brian Finan  2 , Richard D DiMarchi  3 , Matthias H Tschöp  4 , Timo D Müller  5
Affiliations
Review

Insights into incretin-based therapies for treatment of diabetic dyslipidemia

Kerstin Stemmer et al. Adv Drug Deliv Rev. 2020.

Abstract

Derangements in triglyceride and cholesterol metabolism (dyslipidemia) are major risk factors for the development of cardiovascular diseases in obese and type-2 diabetic (T2D) patients. An emerging class of glucagon-like peptide-1 (GLP-1) analogues and next generation peptide dual-agonists such as GLP-1/glucagon or GLP-1/GIP could provide effective therapeutic options for T2D patients. In addition to their role in glucose and energy homeostasis, GLP-1, GIP and glucagon serve as regulators of lipid metabolism. This review summarizes the current knowledge in GLP-1, glucagon and GIP effects on lipid and lipoprotein metabolism and frames the emerging therapeutic benefits of GLP-1 analogs and GLP-1-based multiagonists as add-on treatment options for diabetes associated dyslipidemia.

Keywords: Diabetes; Dyslipidemia; Incretins; Lipoproteins; Obesity.

PubMed Disclaimer

Publication types

MeSH terms